Clinical trial
PEG-Interferon Alfa-2b in Treating Patients With Stage IV Melanoma
NCT00049530 · Eastern Cooperative Oncology Group, Other · Completed
Key facts
| NCT number | NCT00049530 |
|---|---|
| Title | PEG-Interferon Alfa-2b in Treating Patients With Stage IV Melanoma |
| Official title | Phase II Study of Low Dose Peginterferon Alfa-2b in Patients With Metastatic Melanoma Over-Expressing Basic Fibroblast Growth Factor |
| Lead sponsor | Eastern Cooperative Oncology Group, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Melanoma (Skin) |
| Intervention type | Biological |
| Interventions | PEG-interferon alfa-2b |
| Enrollment | 32 |
| Start date | Jan 13, 2004 |
| Primary completion | Aug 1, 2012 |
| Completion | Jun 1, 2014 |
| First posted | Jan 27, 2003 |
| Last update posted | Jun 29, 2023 |
| Countries | United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: